丰明乾 博士、教授、博士生导师


教育经历
1993.9-1997.7 西北农林科技大学作物遗传育种农学学士学位
1997.9-2000.7 西北农林科技大学生物化学与分子生物学理学硕士学位
2005.9-2008.7 南京大学生物学理学博士学位
科研与学术工作经历
2000.7-2005.9 华中农业大学生命科学技术学院 讲师
2008.10-2015.11 美国NIH，博士后，助理研究员（Research Fellow）
2011.12至今，华中农业大学教授
研究方向
抗体工程，肿瘤免疫学，病毒免疫学
代表性研究成果
发表论文
1. Gao W, Tang Z, Zhang YF, Feng M, Qian M, Dimitrov DS, Ho M.Immunotoxin targeting glypican-3 regresses liver cancer
viadual inhibition of Wnt signalling and protein synthesis. Nat Commun. 2015, 6:6536
2. Feng M, Gao W, Wang R, Chen W, Man Y, Fig WD, Wang X, Dimitrov DS, and Ho M. Therapeutically targeting glypican-3
viaa conformation-specific single-domain antibody in hepatocellular carcinoma. Proc Nat Sci Acad USA. 2013, 110:
E1083-91.
3. Feng M, Ho M. Glypican-3 antibodies: a new therapeutic target for liver cancer. FEBS Lett. 2014, 588:377-82.
4. Gao W, Kim H, Feng M, Phung Y, Xavier CP, Rubin JS, Ho M. Inactivation of Wnt signaling by ahumanantibodythat
recognizesthe heparan sulfate chains of glypican-3 for liver cancer therapy. Hepatology, 2014, 60:576-87
5. Tang Z, Feng M, Gao W, Phung Y, Chen W, Chaudhary A, St Croix B, Qian M, Dimitrov DS, and Ho M. A human single-
domainantibody elicits potent anti-tumor activity by targeting an epitope in mesothelin close to the cancer cell surface.
Mol Cancer Ther, 2013, 12: 416-26.
6. Feng M., Kim H., Phung Y., and Ho M. Recombinant soluble glypican3 protein inhibits the growth of hepatocellular
carcinoma in vitro. Int J Cancer, 2011, 128:2246-2247.
7. Feng M., Zhang J., Anver M, Hassan R., and Ho M. In vivo imaging of human malignant mesothelioma grown
orthotopically in the peritoneal cavity of nude mice. J Cancer, 2011, 2: 123-131.
8. Ho M., Feng M., Fisher R.J., Rader C., and Pastan I. A novel high affinity human monoclonal antibody to mesothelin.
Int J Cancer., 2011, 128: 2020-2030.
9. Xiang X, Feng M,Felder M, Connor JP, Man YG, Patankar MS, and Ho M. HN125: A Novel Immunoadhesin Targeting
MUC16 with Potential for Cancer Therapy. J Cancer, 2011, 2:280-91.
10. Xiang X., Phung Y.,Feng M., Nagashima K., Zhang J., Broaddus V.C., Hassan R., FitzGerald D., and Ho M. The
developmentand characterization of a human mesothelioma in vitro 3D model to investigate immunotoxin therapy.
Plos one, 2011, 6: e14640.
11. Yu L., Feng M., Kim H., Phung Y., Kleiner D.E., Gores G..J., Qian M., Wang X.W., and Ho M. Mesothelin as a potential
therapeutic target in human cholangiocarcinoma. J Cancer,2010, 1:141-149.
授权专利
1. Human monoclonal antibodies specific for glypican-3 and use thereof. PCT application no. PCT/US2012/034186; International
filling date 19/Apr/2012. Inventors: Ho M,Feng M, Gao W, Kim H, and Dimiter D.
2. Mesothelin antibodies and methods for eliciting potent antitumor activity. U.S. PCT/US2013/059883. Inventors: Ho M, Pastan
I, Dimitrov DS, Tang Z, Feng M, and Gao W
主讲课程
《免疫学》
研究生招生专业
生物化学与分子生物学
联系方式
实验室电话：，电子邮箱：fengmingqian@mail.hzau.edu.cn